2021-000014-42: A clinical study to assess the safety and efficacy of a liquid for inhalation of budesonide (AQ001S) to treat adults with COVID-19 related respiratory disease. Etude de la sécurité et de l'efficacité d'un liquide pour inhalation de budésonide dans le traitement de troubles respiratoires liés au COVID-19. |
|
|
| Not yet recruiting | 2 | 99 | Europe | Budesonide inhalation solution 0.125 mg/ml, AQ001S 0.125 mg/ml, Inhalation solution | Aquilon Pharmaceuticals, Aquilon Pharmaceuticals | COVID-19 related respiratory disease Troubles respiratoires liés au COVID-19, COVID-19 related respiratory disease Troubles respiratoires liés au COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
SIROCCO-1, NCT05000346: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms |
|
|
| Terminated | 2 | 21 | Europe | Drug, inhalation, inhaled drug, including placebo | Aquilon Pharmaceuticals S.A. | Covid19 | 12/22 | 12/22 | | |
BOREAS, NCT04933383: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics |
|
|
| Completed | 1/2 | 23 | Europe | AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml | Aquilon Pharmaceuticals S.A. | Asthma | 12/22 | 01/23 | | |
